Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the efficacy and safety of a combination of the
anti-CD20 monoclonal antibody Rituximab, Dexamethasone, daily high dose Cytarabine twice, and
Carboplatin; delivered in an outpatient setting.